Last reviewed · How we verify
OriCAR-017
At a glance
| Generic name | OriCAR-017 |
|---|---|
| Sponsor | OriCell Therapeutics Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study (PHASE1)
- OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OriCAR-017 CI brief — competitive landscape report
- OriCAR-017 updates RSS · CI watch RSS
- OriCell Therapeutics Co., Ltd. portfolio CI